Expo is the most significant annual health and social care event in the calendar, uniting more NHS and care leaders, commissioners, clinicians, voluntary sector partners, innovators and media than any other health and care event.
Expo 15 returned to Manchester and was hosted once again by NHS England. Around 5000 people a day from health and care, the voluntary sector, local government, and industry joined together at Manchester Central Convention Centre for two packed days of speakers, workshops, exhibitions and professional development.
This year, Expo was more relevant and engaging than ever before, happening within the first 100 days of the new Government, and almost 12 months after the publication of the NHS Five Year Forward View. It was also a great opportunity to check on and learn from the progress of Greater Manchester as the area prepares to take over a £6 billion devolved health and social care budget, pledging to integrate hospital, community, primary and social care and vastly improve health and well-being.
More information is available online: www.expo.nhs.uk
Keith Ridge, CBE Chief Pharmaceutical Officer
Presentation from the Winterbourne Medicines Programme Launch held in London on 10 September 2014
Ensuring safe, appropriate and optimised use of medication for people with learning disabilities who demonstrate behaviour that can challenge
Breakout 4. 2 Benefits of implementing medicines optimisation in a COPD and a...NHS Improvement
Breakout 4. 2 Benefits of implementing medicines optimisation in a COPD and asthma clinic - Clare Watson
Medicines Management Pharmacist (NHS Hampshire)
Independent Prescriber (Victoria Practice, Aldershot)
Part of a set of presentations from NHS Improvement event: Better value, better outcomes held on Thursday 21 February 2013,
Guoman Tower Hotel, London
How to deliver quality and value in chronic care:sharing the learning from the respiratory programme
Keith Ridge, CBE Chief Pharmaceutical Officer
Presentation from the Winterbourne Medicines Programme Launch held in London on 10 September 2014
Ensuring safe, appropriate and optimised use of medication for people with learning disabilities who demonstrate behaviour that can challenge
Breakout 4. 2 Benefits of implementing medicines optimisation in a COPD and a...NHS Improvement
Breakout 4. 2 Benefits of implementing medicines optimisation in a COPD and asthma clinic - Clare Watson
Medicines Management Pharmacist (NHS Hampshire)
Independent Prescriber (Victoria Practice, Aldershot)
Part of a set of presentations from NHS Improvement event: Better value, better outcomes held on Thursday 21 February 2013,
Guoman Tower Hotel, London
How to deliver quality and value in chronic care:sharing the learning from the respiratory programme
ECO 11: Medicines Optimisation Through Precision - Sir Munir PirmohamedInnovation Agency
Munir Pirmohamed discusses the potential impact of medicines optimisation in terms of ensuring the right patients get the right choice if medicine at the right time. He presents a case history of over prescription and introduces three examples of medicines optimisation through use of genetics, big data, and pharmacogenetics profiling.
A brief presentation on medicines optimisation and the input a clinical pharmacist can make in improving treatment outcomes for patients and help make evidence led cost effective improvements for the wider NHS.
ECO 11: Medicines Optimisation in Northern Ireland - Frans van AndelInnovation Agency
Frans introduces the work of the Medicines Optimisation Innovation Centre based in Northern Ireland. He talks about their background; aims and how they achieve them; and current key initiatives. Frans also discusses the ongoing work of MOIC in enabling technology, the pharmaceutical industry, knowledge transfer, training and education, and other key initiatives.
ECO 11: Transfer of Care to Pharmacy - Hassan Argomandkhah, Chair of Pharmacy...Innovation Agency
Hassan introduces the concept and key objectives of transfer of care to pharmacy (TCP). The slides include a project outline, an overview of TCP in Cheshire and Merseyside, and the benefits and potential savings of Electronic Transfer of Care to Pharmacy.
American Public Health Association- Annual Meeting 2014 Presentation scherala
Title: Using Quantitative Data to focus Medical Home Facilitation Interventions in the Massachusetts Patient Centered Medical Home Initiative (MA PCMHI)
3.2 Hubs and collaboration - Greg Kalita, Dave BearmanNHS England
Hubs and collaboration. Hub-based working and collaborating across boundaries to improve access and care. Including examples from Sheffield, Devon and Cornwall. Greg Kalita and Dave Bearman, Northern, Eastern & Western Devon and South Devon & Torbay CCGs.
From effectively implementing electronic health records to reducing hospital readmissions to reporting more specific Medicare patient data, health care providers are reaping rewards from the Centers for Medicare and Medicaid Services for improving particular quality and safety measures. But many are also facing penalties, and the results for some institutions have been mixed. On the whole, the national readmission rate is dropping, but in 2014 a record 2,600-plus hospitals were fined for seeing too many patients return for care within 30 days, according to federal data.
This session will help attendees understand the range of CMS cuts and bonuses and a firsthand look at how the new regulations can help providers improve care.
How to achieve the NICE guidelines on Managing Medicines in Care HomesKarisBrummitt
The NICE Quality Standard on Managing Medicines in Care Homes is due for publication in March 2015. A NICE Quality Standard is a concise set of statements designed to drive and measure improvements in quality. They are based on national guidelines (including NICE guidelines which consist of around 90 recommendations) and can be used to review services, highlight areas where quality needs to be improved and offer suggestions as to how this can be achieved.
www.interlinkconsultancy.com
Healthcare industry challenges and pharmacoeconomic solutions.The pharma industry product pipelines are drying up, leading to a high dependence on existing products for survival. The branded generic drugs segment has become commoditized due to ever increasing and fierce
competition.Price plays a major role in drug prescription and buying decisions. High price may not always assure high quality or more benefits and companies are finding it difficult to substantiate higher prices..
ECO 11: Medicines Optimisation Through Precision - Sir Munir PirmohamedInnovation Agency
Munir Pirmohamed discusses the potential impact of medicines optimisation in terms of ensuring the right patients get the right choice if medicine at the right time. He presents a case history of over prescription and introduces three examples of medicines optimisation through use of genetics, big data, and pharmacogenetics profiling.
A brief presentation on medicines optimisation and the input a clinical pharmacist can make in improving treatment outcomes for patients and help make evidence led cost effective improvements for the wider NHS.
ECO 11: Medicines Optimisation in Northern Ireland - Frans van AndelInnovation Agency
Frans introduces the work of the Medicines Optimisation Innovation Centre based in Northern Ireland. He talks about their background; aims and how they achieve them; and current key initiatives. Frans also discusses the ongoing work of MOIC in enabling technology, the pharmaceutical industry, knowledge transfer, training and education, and other key initiatives.
ECO 11: Transfer of Care to Pharmacy - Hassan Argomandkhah, Chair of Pharmacy...Innovation Agency
Hassan introduces the concept and key objectives of transfer of care to pharmacy (TCP). The slides include a project outline, an overview of TCP in Cheshire and Merseyside, and the benefits and potential savings of Electronic Transfer of Care to Pharmacy.
American Public Health Association- Annual Meeting 2014 Presentation scherala
Title: Using Quantitative Data to focus Medical Home Facilitation Interventions in the Massachusetts Patient Centered Medical Home Initiative (MA PCMHI)
3.2 Hubs and collaboration - Greg Kalita, Dave BearmanNHS England
Hubs and collaboration. Hub-based working and collaborating across boundaries to improve access and care. Including examples from Sheffield, Devon and Cornwall. Greg Kalita and Dave Bearman, Northern, Eastern & Western Devon and South Devon & Torbay CCGs.
From effectively implementing electronic health records to reducing hospital readmissions to reporting more specific Medicare patient data, health care providers are reaping rewards from the Centers for Medicare and Medicaid Services for improving particular quality and safety measures. But many are also facing penalties, and the results for some institutions have been mixed. On the whole, the national readmission rate is dropping, but in 2014 a record 2,600-plus hospitals were fined for seeing too many patients return for care within 30 days, according to federal data.
This session will help attendees understand the range of CMS cuts and bonuses and a firsthand look at how the new regulations can help providers improve care.
How to achieve the NICE guidelines on Managing Medicines in Care HomesKarisBrummitt
The NICE Quality Standard on Managing Medicines in Care Homes is due for publication in March 2015. A NICE Quality Standard is a concise set of statements designed to drive and measure improvements in quality. They are based on national guidelines (including NICE guidelines which consist of around 90 recommendations) and can be used to review services, highlight areas where quality needs to be improved and offer suggestions as to how this can be achieved.
www.interlinkconsultancy.com
Healthcare industry challenges and pharmacoeconomic solutions.The pharma industry product pipelines are drying up, leading to a high dependence on existing products for survival. The branded generic drugs segment has become commoditized due to ever increasing and fierce
competition.Price plays a major role in drug prescription and buying decisions. High price may not always assure high quality or more benefits and companies are finding it difficult to substantiate higher prices..
Clinical Pharmacology in Orphan Drug DevelopmentE. Dennis Bashaw
This is the fourth talk that I gave in Asia back in May. It was presented at the Konect (Korea National Enterprise for Clinical Trials) 3rd symposia that was held in Seoul at Seoul National University.
CME presentation made on 10th Nov 2012. Discusses a Radiation Oncologist's perspectives of cancer pain management, shortcomings of WHO pain ladder, ASTRO guidelines for metastatic bone pain.
Geriatric Population. Pain and Palliative Care for the Older (Geriatric) AdultMichelle Peck
Michelle Peck | Legal Nurse | Nurse Practitioner | Health Care | Geriatric | Consultant | Speaker | Educator | Researcher
During your journey through this slide deck of Geriatric Populations, Pain and Palliative Care for the Older (Geriatric) Adult, you will experience: the assessment of pain; pain management strategies; and learn more about Palliative Care services.
As a health care consumer it is important to recognize and be aware of the quality of life benefits of good pain and symptom control. This begins with a good assessment of the factors contributing to the pain. Pain is a multifaceted experience. There are many barriers to achieving effective pain control in the elderly (geriatric population). Health care providers need to be aware of personal biases surrounding pain for proper pain management. There are also many health care provider misconceptions regarding Palliative Care especially in the geriatric population.
To enrich your geriatric understanding, at the end of this slide deck we discuss Palliative Care: the relief you need when you are experiencing serious medical illness.
Learn it-Live it-Love it-Your path for a more informed life!
Michelle Peck | Legal Nurse | Nurse Practitioner | Health Care | Geriatric | Consultant | Speaker | Educator | Researcher
Shelagh Morris, Allied Health Professions Officer of the Department of Health, talks about supplementary prescription. COT Annual Conference 2010 (22-25 June 2010)
Graham was invited to the weekly seminar series by the Royal Brompton Hospital to deliver a presentation on health economics pertinent to Respiratory medicine. They care for a large number of patients with complex lung diseases at the institution and juggle the varied issues of resource (human, structural or financial). As one of many examples, high cost drugs for treating relatively unusual conditions comes up for debate all too frequently. The audience included consultant physicians, senior and junior trainees, nurses and other allied health professionals.
Date: 7 March 2019
Location: The Royal Brompton, London, UK
Ομιλία – Παρουσίαση: Raymond Anderson, President Commonwealth Pharmaceutical Association and Member of the Pharmacovigilance Risk Assessment Committee (PRAC) at EMA
«Best Practices to inform citizens on Self-medication»
MicroGuide app, pop up uni, 1pm, 3 september 2015NHS England
Expo is the most significant annual health and social care event in the calendar, uniting more NHS and care leaders, commissioners, clinicians, voluntary sector partners, innovators and media than any other health and care event.
Expo 15 returned to Manchester and was hosted once again by NHS England. Around 5000 people a day from health and care, the voluntary sector, local government, and industry joined together at Manchester Central Convention Centre for two packed days of speakers, workshops, exhibitions and professional development.
This year, Expo was more relevant and engaging than ever before, happening within the first 100 days of the new Government, and almost 12 months after the publication of the NHS Five Year Forward View. It was also a great opportunity to check on and learn from the progress of Greater Manchester as the area prepares to take over a £6 billion devolved health and social care budget, pledging to integrate hospital, community, primary and social care and vastly improve health and well-being.
More information is available online: www.expo.nhs.uk
This research explores the feasibility of introducing an Outcome-Based Payment approach for new cancer drugs in England. A literature review explored the current funding landscape in England, the available evidence on existing OBP schemes internationally, and
which outcomes cancer patients value most. Two focus groups and an online survey with patients and carers, as well as interviews with NHS and government stakeholders, healthcare
professionals, and pharmaceutical industry representatives, provided additional evidence on the feasibility and suitability of OBP schemes
An introduction to medication therapy managementKabito Kiwanuka
Pharmacists: An Untapped Resource: Pharmacists receive more training on the safe, effective and appropriate use of medications than any other healthcare professional
1.3 Develop the team - pharmacists - Ravi SharmaNHS England
Develop the team - pharmacists. Using clinical pharmacists as part of the practice team. Featuring experience from the national clinical pharmacists programme. Ravi Sharma, clinical lead for NHS England's clinical pharmacy programme.
Presentation by Dr Binita Kane, Manchester University NHS Foundation Trust: Innovation in integrated care, at ECO 21 event at Haydock Park Racecourse on Thursday 12 December 2019.
Health Economics In Clinical Trials - Pubricapubrica101
Pubrica specializes in Health Economics in Clinical Trials, offering comprehensive support to ensure the economic aspects of your trial are effectively managed. From cost-effectiveness analysis to budgeting and reimbursement strategies, we help you optimize the economic outcomes of your trial. With Pubrica's expertise, you can navigate the complex landscape of health economics in clinical trials with confidence.
For more information, please refer to our service- https://pubrica.com/blog/research/health-economics-in-clinical-trials/ & Order now - https://pubrica.com/order-now/
Contact Our UK Medical Author’s;
Our email id – sales@pubrica.com
Contact No. +91 9884350006
QA Paediatric dentistry department, Hospital Melaka 2020Azreen Aj
QA study - To improve the 6th monthly recall rate post-comprehensive dental treatment under general anaesthesia in paediatric dentistry department, Hospital Melaka
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
2. What is medicines optimisation?
Dr Keith Ridge
Chief Pharmaceutical Officer
NHS England
3. Medicines:
• Prevent life-threatening diseases
• Help to change previously life-threatening illnesses to long-term
conditions eg HIV
• Improve the quality of life for people with long-term conditions
• Reduce mortality acrossa wide range of diseases and thereby help
increase life expectancy
Medicines have a vital role to play
4. Medicines Optimisation in practice
Medicines are still the most common therapeuticintervention and
the biggest NHS cost after staff, but there are some fundamental
issues that need to be addressed.
5. Patients report haveinsufficient
supportinginformation
UK Literature suggests 5 to 8% of hospital
admissions due to preventable adverse
effects of medicines
Medicines wastage in primary
care: £300M pa with £150M pa
avoidable
The threat ofantimicrobial
resistance
Appropriate vs.inappropriate polypharmacy.
Multi-morbidityand polypharmacyincrease
clinical workload
30 - 50% of medicines not taken as
intended
Medication errors across all
sectors and age groups at
unacceptable levels
Uptake of newer medicines
can be patchyand unwarranted
variation in use of medicines
Relativelylittle effort towards
understandingclinicaleffectiveness
of medicines in real practice
£14.4 billion spend each year on
medicines by NHS England
(15% of entire NHS Budget)
i
£
£
6. Harnessing this opportunity
The Rt Hon Jeremy Hunt MP, the Secretary of State for
Health wrote to ABPI & NHS England in April and asked that
they work together….
“to agree and carry through a solution foracceleratinguptake of
clinicallyand cost effectivemedicines which maximises the benefits
of the PPRS within the current financial situation.This means an end
to cost containment measureson branded medicines which will not
in the long run save the NHS anymoney.It also means creatinga real
clinical pull forinnovativeand cost effectivemedicines,replacing
costlynon drug treatments bya programmeof cultural change led
jointlybyNHS England and the industryusingall the management
levers available”.
7. The principles of Medicines Optimisation are supported by
NHS England, through Sir Bruce Keogh, Jane Cummings and
Keith Ridge. It also has support from the highest levels
through the Ministerial Industry Strategy Group.
High level support
8. “Medicines optimisation is about ensuring the
right patients, get the right choice of medicine at
the right time”
RPS, Medicines Optimisation: Helping patients to make the most of
medicines, May 2013
10. NHS England and ABPI have
embarked on a joint programme of
work, guided by the Principles of
Medicines Optimisation that were
published by the Royal
Pharmaceutical Society in May
2013.
11. Medicines optimisation looks beyond the cost of medicines to the value they deliver and recognises
medicines as an investment in patient outcomes.
The goal is to help patientsto:
• Improve their outcomes, including better monitoring and metrics
• Have access to an evidence-based choice of medicine
• Improve adherence and take medicines correctly
• Avoid taking unnecessary medicines
• Reduce wastage of medicines
• And improve medicines safety
The goal of medicines optimisation
“Where a medicine or
technology is clinically sound
and cost effective forthe
NHS,patients should have
access to it – no question, no
qualification.”
Baroness Barbara Young, Chair,
Diabetes UK
12. • Identifying the role MO has to play in local system redesign
and integrated care
• A move from the ‘cost’ to the ‘value’ discussion
• Identification of the role MO has to play in defining what the
next 5 years looks like
• A new approach of value in system redesign rather than
doing things as we have done for the past 20 years
• Commissioning of innovative medicines where they show
overall value
• Identifying the role of MO in delivering £22bn system
efficiencies over the 5year Forward View
What does PPRS/MO facilitate?
13. • Establishing meaningful patient engagement on medicines
optimisation
• Further developing the medicines optimisation dashboard
• Specialised commissioning: utilisation of “commissioning through
evaluation”
• NICE Clinical Guideline on medicines optimisation (March 2015) and
implementation support workshops
• Developing medicines optimisation strategy and best practice
resource
• Winning hearts and minds:
– Joint NHS England/ABPIroadshows with AHSNs
– Working with senior clinical leaders
– Engaging NHS finance professionals
– Strategic communications plan
Outline work programme
Medicines
Optimisation
NHSE
NICE
AHSN
HCP
Patients
ABPI
14. Examples of Medicines Optimisation in
practice
Andrew Cooke MRPharmS
Assistant Director
Head of Medicines Optimisation
Bedfordshire CCG
15. Optimising the use of inhalers in
Bedfordshire care homes
• Reviewed and supported 191 patients prescribed
inhalers within 59 care homes
• Provided training workshops for care home staff
• On site pharmacy technician review of care
home drug rounds
17. • Patients:
– Are more mobile (less breathless)
– Have improved well-being
– Have improved mood
– Are more engaged in activities
– Have improved appetite.
All set out as objectives at outset and recorded, however these are
subjective measures, so cannot be considered conclusive
18. Medicines Optimisation Pharmacy
Service (MOPS)
Aim:
• To provide a full clinical medication review service by a specialist pharmacist
to Community patients 75yrs+, assessed at risk of hospital admission and
having complex medication needs
19. 1. Full clinical medication reviews completed by clinical
pharmacists in patients homes across 3 CCGs:
• Check clinical appropriateness of prescribed medication, i.e. doses, duration,
frequency.
• Review of long term medication.
• Management of adverse drug reactions and side effects.
• Adherence assessment, e.g. day to day management of medicines, inhaler
technique.
2. Pharmaceutical care plan agreed with patient
• Recommendations made to GP & multidisciplinary team.
• Support provided to help with medication administration.
• Communication/referral to district nurses, community pharmacists
(MUR/NMS), specialist nursing teams (COPD, heart failure, diabetes).
20. Results
• A full clinical medication review was conducted on 387 patients
across three CCGs.
• In summary, of the 1,799 interventions made:
21. Cost per patient (average)
• Table 4 – Cost savings (£) per patient Average
Comparing the costs of medicines stopped and the cost of the
pharmacist, the service is cost neutral, at 6 month post review
22. Fewer non-elective hospital
admissions (6 month data (N=353))
Statistical analysis using Wilcoxon signed rank test with continuity correction.
p-value = 0.03096, suggests a significant change after pharmacist reviews.